Cholesterol Granulomas (CG) are benign cysts that grow in a special type of middle ear granulation tissue known as the petrous apex (located near the part of the skull that is next to the middle ear). This area is particularly prone to bleeding and can cause hemotympanum. Cholesterol granulomas are cysts that contain fluids, lipids, and cholesterol crystals, surrounded by a fibrous lining. These cysts can grow anywhere throughout the body as they develop as a reaction for foreign material. Specifically, they are created with the air cells in the area are obstructed, causing a vacuum that draws blood into the air cells. The decomposition of blood releases cholesterol which triggers an inflammatory response. Middle aged individuals with a history of chronic otitis media are the most affected subgroup of patients that develop CG. One of the most common treatments for cholesterol granulomas is endoscopic endonasal approach (EEA).
Cholesterol Granuloma Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Cholesterol Granuloma below!
For more information on how to use Laverne, please read the How to Guide.
We have 988 products for the study of Cholesterol Granuloma that can be applied to Flow Cytometry, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Cholesterol Granuloma is also known as Cholesterinic Granuloma, Pseudocholesteatoma.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.